Intent to Harm



Evidence of conspiracy to commit mass murder by the pharma manufacturers, US Department of Defense/HHS and other governments

Sasha Latypova, 2023

sashalatypova.substack.com

Summary of All Evidence => Intent to Harm

- **Toxic by Design:** Mechanisms of injury designed into C-19 injections
- **No Safety:** Horrific death and injury toll (VAERS, vSAFE, Eudravigilance, Yellow Card, etc => millions of reports)
- **No Efficacy:** negative efficacy 3+ months after injections
- **Bad Manufacturing:** Highly variable production, non-compliant with cGMP, no enforcement of cGMP by any agency
- **Malignant Policy Worldwide:** Government lies, cover-up, gaslighting of the injured, prosecution of dissent and whistleblowers, collusion with media, perverse financing of the above =>clear **intent to harm**

Pseudo-Legal Structure of this Crime (in the US)

Pseudo-Legalization of EUA-Covered "Military Countermeasures". Most Recent Relevant Legislation Includes:

Emergency Use Authorization (1997 Clinton) – Get rid of the FDA "safety & efficacy" regs under EUA

+

Other Transaction Authority (2015 Obama) – Enable DOD to order undisclosed "military prototypes" from pharma

↓

PREP Act and "Public Health Emergency" 2020 (Trump), continued by Biden to date

Law research by Katherine Watt, Bailiwick News on Substack

“Other Transaction Authority” (OTA)

- “Other” gov contracting with private companies:
  - not contract, not research grant, not procurement, etc., not any normally regulated/accountable contracting
- Allows to order otherwise regulated products bypassing the regulations
- Started in 1960’s for NASA only, now 11 gov agencies use it
- BARDA/DOD/HHS/NIH use OTA extensively and funnel billions to private contractors for vague category of “covid countermeasures”
- Shield private companies from gov rights to taxpayer funded IP incl disclosure (the private companies then reward those government officials with e.g., board positions).
- DOD uses OTA to order vaguely defined “prototypes”, “demonstrations” that are not subject to any regulatory scrutiny

"Military Prototype Countermeasures"

- 10 USC 2371b/10 USC 4022 Other Transaction Authority (OTA) program "legalized" DOD contracting with pharmas to produce bio-chemical weapons, in violation of federal and international laws prohibiting same:
  - 10 USC 4022(a)(1) - "[T]he Director of [] (DARPA), the Secretary of a military department, or any other official designated by the Secretary of Defense may, under the authority of section 4021 of this title, carry out prototype projects that are directly relevant to enhancing the mission effectiveness of military personnel and the supporting platforms, systems, components, or materials proposed to be acquired or developed by the Department of Defense, or to improvement of platforms, systems, components, or materials in use by the armed forces."
- The OTA government purchasing program classified bio/chem/radio/nuclear-weapons as "qualified countermeasures, medical countermeasures and security countermeasures".

weapons

Research by Katherine Watt

"Countermeasures" Deployed at HHS Secretary's Discretion Are NOT Required to Meet Any Standards

Congressional amendments to the 1938 FD&C Act and the 1944 PHS Act had eliminated federal regulatory standards for production and use of products designated by the FDA for "emergency use" during an HHS-declared, HHS-maintained "public health emergency."

21 USC 360bbb-3(c) "Criteria for Issuance of Authorization": the law provides that the HHS Secretary may issue emergency use authorizations if he/she concludes:

- that, based on the totality of scientific evidence available to the Secretary, including data from adequate and well-controlled clinical trials, if available, it is reasonable to believe that–
- (A) the product may be effective in diagnosing, treating, or preventing–
  - (i) such disease or condition; or
  - (ii) a serious or life-threatening disease or condition caused by a product authorized under this section, approved or cleared under this chapter, or licensed under section 351 of the Public Health Service Act [42 U.S.C. 262], for diagnosing, treating, or preventing such a disease or condition caused by such an agent; and
- (B) the known and potential benefits of the product, when used to diagnose, prevent, or treat such disease or condition, outweigh the known and potential risks of the product, taking into consideration the material threat posed by the agent or agents identified in a declaration under subsection (b)(1)(D), if applicable;

DOD and Pfizer agents had means, motive and opportunity, through OTA contracts to ensure that no evidence capable of interfering with the HHS Secretary and FDA regulatory officials (Azar/Kadlec/Gruber) EUA declarations would ever become available

Research by Katherine Watt

Use of EUA Countermeasures is NOT a Clinical Investigation:

- 21 USC 360bbb-3(k): **use** of EUA-covered medical countermeasure (MCM) products, once designated as such by the Secretary of Health and Human Services (March 10, 2020, retroactive to February 4, 2020) "**shall not be considered to constitute a clinical investigation.**"

- Countermeasures are NOT pharmaceutical products

Research by Katherine Watt

FDA Does Not Regulate Countermeasures, and Neither Does EMA



Wuhan spike
141 kDa

https://www.excellgene.com/sars-cov-2-trimeric-spike-protein-wuhan/

"Regulators" DO NOT KNOW what protein is coded by the mRNA injections!

?

Spike protein produced by synthetic mRNA
180kDa

From leaked European Medicines Agency Review of Pfizer Manufacturing Documentation, 2020

[LACK OF]CHARACTERIZATION OF SPIKE PROTEIN

- A severe deficiency of the characterization section is that no biological characterization is presented and that the mode of action is not described. This is not found acceptable and the dossier should be updated with relevant information. Even though full biological characterisation is not possible to perform on drug substance (DS), the strategy to determine potency and relevant functional assay(s) should be described. Results obtained on drug product (DP) could be included, to demonstrate functionality."
  - Became a SPECIFIC OBLIGATION 1 on CMA Dec 20, 2020
  - Still not met Dec 2021
  - Granted Feb 2022

EMA gave up on this issue



Figure 3.2.S.2.6-15. To evaluate expressed protein size, BNT162b2 DS was mixed with Lipofectamine and then transfected into HEK-293 cells. Following incubation, cell lysates were evaluated for the expressed protein antigen by Western blot using an antibody specific for the SARS-CoV-2 spike protein. The first lane shows a molecular weight (MW) marker. The concentrations shown for each DS batch correspond to the amounts of DS transfected per well of HEK-293 cells.

EMA Admitted in Response to FOIA Request

- *"All the Covid vaccines and therapeutics authorisation decisions were taken by the Licensing Minister and were not delegated.*
- *The MHRA does not hold a document describing the flow of delegation from the Secretary of State to posts/people in MHRA who can authorise medicines for public use."*
- Under the Human Medicines Regulations, the Licensing Authority is the Secretary of State for Health. He or she delegates to MHRA all the work associated with that – licensing of medicines, pharmacovigilance, inspection of manufacturers, enforcement and so on.
- But for the Covid vaccines, MHRA is saying that the Secretary of State personally took all the decisions.

Org Structure of the Crime

National Security Council set the Covid Policy

- The NSC is an executive forum for foreign policy and national security and does not include public health-related agencies.
- Regular attendees (both statutory and non-statutory) are:
  - Vice President
  - Secretary of State
  - Secretary of the Treasury
  - Secretary of Defense
  - Assistant to the President for National Security Affairs.
  - Chairman of the Joint Chiefs of Staff is the statutory military advisor to the Council
  - Director of National Intelligence is the intelligence advisor

Decisional Role



Pandemic response org chart, from p. 9 of ***Pandemic Crisis Action Plan- Adapted, 2020 (PanCAP-A)***, showing the NSC solely responsible for Covid policy

Operation Warp Speed

HHS and DoD working collaboratively with other federal partners as "One Government entity" to address the largest health security threat our nation has faced in a century.

Partnering with the biotech and pharmaceutical industry to develop, manufacture, deliver and administer safe and effective vaccines, and therapeutics to prevent and treat COVID-19 that will mitigate the effects of COVID-19 in the United States.

Not in charge: Pharma companies ($$$$)

In charge: NSC, DOD, BARDA



Who is REALLY developing and manufacturing these injections?

As of October 20, 2020

OWS/BARDA Vaccine Manufacturing Portfolio



Mfg = ≥100M doses

Accelerating Development of Safe and Effective Vaccines



- Platform Technologies
- Multiple Candidates
- Large Scale Manufacturing in Parallel with Clinical Trials
- Large Phase III Trials

- Violation of cGMP (CFR Title 21*)
- Not possible to manufacture <u>safe</u> products before safety is properly tested
- "Platforms" do not exempt each product from full safety testing requirements

*https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations

RQA Accomplishments in 2022

- Product acceptance of **over 600,000M** COVID-19 vaccin doses and **over 23M** COVID-19 therapeutic doses
- Increased Industry and Regulatory Surveillance
- Good Manufacturing Practices/Quality System audits to assess preparedness for new contracts for pandemic flu
- Productive and successful collaborations with USG partn



The Money Flow

Partners/Commitment to Stakeholders

61 FDA Approvals, Licensures, and Clearances

BARDA'S Early Investments Paved the Way for Federal COVID-19 Response Success





2021

CT REGENERON
casirivimab & Imdevimab (SARS-CoV-2 specific mAbs) & Mfg.
Demo
EUA

CT Roche Genentech
Anti-IL6R mAb (Actemra®)
EUA

CT
Convalescent Plasma
EUA

CT Lilly
Bamlanivimab & Etesevimab
EUA

CT moderna
mRNA-1273 Commercial Scale Mfg
EUA

CT Johnson&Johnson janssen
Ad26 COVID-19 Vaccine Mfg
Demo
EUA

CT AstraZeneca
AZD1222 (ChAdOx1) R&D and Commercial Scale Mfg

CT gsk SANOFI PASTEUR
Recombinant Protein + AS03 Adjuvant Mfg. Demo

CT Pfizer
BNT162 (mRNA) Commercial Scale Mfg (Comirnaty)
BLA



Source: BARDA "Industry Day" webinar, November 2022

by KEI. ***Linked herein is a comprehensive list of all US government COVID-19-related contracts obtained by KEI via FOIA.***

- **Advanced Technology International (ATI) – Underlying contract to execute MCDC and COVID-19 contracts on behalf of the federal government**.
  - DoD-ATI Other Transaction Authority Agreement W15QKN1691002-P00085. April 8, 2016.
  - DoD-ATI Other Transaction Authority Agreement W15QKN1691002-P00085. April 8, 2016. (Version obtained November 30, 2020 from HHS FOIA Reading Room)
- **Aerpio – respiratory condition treatment**.
  - DOD-Aerpio Statement of Work W81XWH1590001.
  - DOD-Aerpio Project Approval Letter W81XWH1590001. July 28, 2020.
- **Altimmune – therapeutic.**
  - DoD-Altimmune Project Approval Letter W81XWH159001. June 17, 2020.
  - DoD-Altimmune Statement of Work W81XWH159001.
  - DoD-Altimmune Revised Project Approval Letter (3) W81XWH159001. February 3, 2021.
  - DoD-Altimmune Revised Project Approval Letter (2) W81XWH159001. December 15, 2020.
- **America's Blood Center – convalescent plasma**.
  - HHS/ASPR/BARDA-America's Blood Center Contract 75A50120000094 (includes Mods 1-8). April 17, 2020.
  - DOD-America's Blood Centers Contract W911QY2190006. October 30, 2020.
- **ANP Technologies – diagnostics.**
  - DoD-ANP Technologies Contract W911QY20D0019 (includes Mods 1-3). May 29, 2020.
  - DOD-ANP Technologies Supply Order W911QY20D0019 (includes Mods 1-3). June 2, 2020.
  - DOD-ANP Technologies Supply Order W911QY20P0141 (includes Mod 1). April 17, 2020.
- **AstraZeneca – vaccine.**
  - HHS/ASPR/BARDA-AstraZeneca Advanced Agreement to Other Transaction Authority Agreement 75A501-20-C-00114. May 20, 2020.
  - HHS/ASPR/BARDA-AstraZeneca Modification of OTA Agreement 75A501-20-C-00114 MODP00001. July 31, 2020.
- **AstraZeneca – vaccine.**
  - DoD-AstraZeneca Other Transaction Authority Agreement W15QKN2191003. October 28, 2020.
- **AstraZeneca – prophylactic monoclonal antibody.**
  - DOD-AstraZeneca Contract W911QY2190001 (includes Mods 1, 2, 3, and 5). October 9, 2020.
- **AstraZeneca – therapeutic.**
  - DoD-AstraZeneca Contract W911QY20C0119 (includes Mod 1). September 30, 2020.
  - DoD-AstraZeneca Contract W911QY20C0119 (includes Mod 1). September 30, 2020. (Version obtained by FOIA)
- **Atlantic Diving Supply – no-contact thermometers**.
  - DOD-Atlantic Diving Supply Contract W911QY18D0019. September 16, 2020.
- **Beckman Coulter – diagnostic-related.**
  - HHS/ASPR/BARDA-Beckman Coulter Contract 75A50119C00078. September 30, 2019.
  - HHS/ASPR/BARDA-Beckman Coulter Contract 75A50119C00078-P00001. May 15, 2020.
  - HHS/ASPR/BARDA-Beckman Coulter Contract 75A50120C00189. September 28, 2020.
- **Biofire Defense – diagnostics.**
  - DoD-Biofire Defense Supply Order W911QY13D0080 Contract W911QY20F0271. April 24, 2020.
  - DoD-Biofire Defense Supply Order W911QY13D0080 Contract W911QY20F0171 (includes Mods 1-2). May 23, 2020.
  - DOD-Biofire Defense Supply Order W911QY20F0196 and W911QY20F0165 Contract W911QY13D0080 (includes Mod 1 of W911QY20F0196). April 17, 2020.
- **BCG Federal Corp – COVID-19-related support services.**

- All contracts from DOD via ATI "management company", not directly with government
- Robert Kadlec (ASPR Secretary under Trump) personally controlled $$$ contracts.
- Kadlec lead "update" to PREP Act to fully shield pharmas from liability. Ex-lobbyist for Emergent Biosolutions, a defense manufacturer which got contract to made J&J and AZ covid vaccines.

Full list available at https://www.keionline.org/covid-contracts



WE ACCELERATE IMPACT

We bring together the best and brightest from industry and academia to solve our nation's most complex challenges.

LEARN ABOUT OUR APP

We help the government quickly acquire cutting-edge technologies.

Weapons

medcbrn.org/current-members/

Member Login | Govt Login | New User? Request Access | BIDS Portal | Contact Us |

MCDC Medical CBRN Defense Consortium
Prevent | Diagnose | Treat

MCDC | Membership | OTA | Solicitations | News & Events | Contact Us

Current Members

87%

Non-Traditional

316

Current Members

* indicates Non-Traditional Member



Small Organization Members

7 Hills Pharma LLC *
AAG Associates LLC *
AbViro LLC *
Acer Therapeutics, Inc. *
Action Medical Technologies *
Adagio Therapeutics, Inc. *
Adaptive Phage Therapeutics, Inc. *
Aegis BioDefense, Inc. *
AktiVax *
Alchem Laboratories Corp. *

Academic Members

Auburn University *
Boston University *
Duke University
Emory University *
George Mason University
Icahn School of Medicine at Mount Sinai *
Indiana University *
Iowa State University of Science and Technology *
Northern Arizona University
The Washington University *

"Vaccine Development and Approval"- a performance art to convince the public

- The word "demonstration" (i.e. fake) in DOD contracts for vaccines
- Clinical trials were not ordered by DOD/HHS - not possible for countermeasures
- cGMP compliance was not ordered - not possible
- Legally there were no clinical trial subjects or investigators, and no informed consent

FDA leadership are impersonating the regulators and lying to the public – they have no authority to regulate countermeasures

Review of DOD Contracts for Countermeasures

- DOD had established vax manufacturing and "surge capacity" since at least 2012:
  - Millions of sq ft manufacturing capacity
  - Staff, raw materials, assays, kits, manufacturing equipment, logistics, systems, etc.
- DOD-Pharma contracts for C-19 injections "switched on" the machine:
  - No pharma capacity to fulfill contracts in time except via DOD established infrastructure
  - No accountability other than "reasonable effort"
  - Micro-management of operations, clinical, regulatory from DOD (not "arms length")
  - Product vials not serialized, shipped to DOD (not pharma distributor)
  - Product described explicitly as "civil and military application"
- Ex-US Pharma-foreign gov contracts:
  - Waive any relevant drug import regulations, rules, standards, etc.
  - Remove national sovereignty, prohibit changing of national laws to make pharma liable for injury
  - Prohibit independent vial testing of imported product

33

34

35

36



H.8 Public Readiness and Emergency Preparedness (PREP) Act:

In accordance with the Public Readiness and Emergency Preparedness Act ("PREP Act"), Pub. L. No. 109-148, Division C, Section 2, as amended (codified at 42 U.S.C. § 247d-6d and 42 U.S.C. § 247d-6e), as well as the Secretary of HHS's Declaration Under the Public Readiness and Emergency Preparedness Act for Medical Countermeasures Against COVID-19, 85 Fed. Reg. 15198 (Mar. 17, 2020, effective Feb. 4, 2020), and amended on April 15, 2020, 85 Fed. Reg. 21012 (together, the "Prep Act Declaration"):

(i) This Agreement is being entered into for purposes of facilitating the manufacture, testing, development, distribution, administration, and use of "Covered Countermeasures" for responding to the COVID-19 public health emergency, in accordance with Section VI of the PREP Act Declaration;

(ii) Contractor's performance of this Agreement falls within the scope of the "Recommended Activities" for responding to the COVID-19 public health emergency, to the extent it is in accordance with Section III of the PREP Act Declaration; and

(iii) Contractor is a "Covered Person" to the extent it is a person defined in Section V of the PREP Act Declaration.

DOD-Moderna contract, PREP Act Clause

Therefore, in accordance with Sections IV and VII of the PREP Act Declaration as well as the PREP Act (42 U.S.C. § 247d-6d), the Department of Defense contracting via assisted acquisition on behalf of the HHS, expressly acknowledges and agrees that the HHS Declaration cited above, specifically its language providing immunity from suit and liability is applicable to this acquisition as long as Contractors activities fall within the terms and conditions of the PREP Act and the PREP Act Declaration.

The Government may not use, or authorize the use of, any products or materials provided under this contract, unless such use occurs in the United States (or a U.S. territory where U.S. law applies such as embassies, military and NATO installations) and is protected from liability under a declaration issued under the PREP Act, or a successor COVID-19 PREP Act Declaration of equal or greater scope. Any use where the application of the PREP Act is in question will be discussed with Moderna prior to use and, if the parties disagree on such use, the dispute will be resolved according to the "Disputes Clause" (52.233-1)

The items and technology covered by this Contract are being developed for both civil and military applications.

(b) (4) [redacted]

Pfizer Contract

1.2 Scope

The scope of this prototype project is the demonstration by Pfizer of the supply and logistics capability to manufacture and distribute to the Government of 100M doses of a novel mRNA-based vaccine that has received FDA-approval or authorization based on demonstration of efficacy (hereafter FDA-approved or authorized). The criteria for successful Emergency Use Authorization (EUA) are described in *Emergency Use Authorization of Medical Products and Related Authorities: Guidance for Industry and Other Stakeholders, January 2017*; and *Development and Licensure of Vaccine to Prevent COVID-19: Guidance for Industry June 2020*. The successful provision of these doses shall establish the effectiveness of a technology capable of potentially providing immediate and long-term solutions to coronavirus infections. While pre-clinical, clinical, and chemistry/manufacturing/controls (CMC) activities are described in the Background section of this Statement of Work, the Parties acknowledge and agree that such activities not related to the large-scale manufacturing demonstration are out-of-scope for this prototype project as Pfizer and BioNTech have and will continue to fund these activities, without the use of Government funding.

Pfizer Contract

DEPARTMENT OF THE ARMY
U.S. ARMY CONTRACTING COMMAND – NEW JERSEY
PICATINNY ARSENAL, NEW JERSEY 07806-5000

REPLY TO
ATTENTION OF

21 July 2020

Army Contracting Command – New Jersey
ACC-NJ, Building 9
Picatinny Arsenal, NJ 07806

SUBJECT: Technical Direction Letter for Medical CRBN Defense Consortium (MCDC), Request for Prototype Proposals (RPP) 20-11, Objective PRE-20-11 for "COVID-19 Pandemic – Large Scale Vaccine Manufacturing Demonstration" (Pfizer, Inc.)

REF: Prizer Request for Technical Direction Letter, RPP 20-11 under OTA W15QKN-16-9-1002 for Objective PRE-20-11, dated 20 July 2020

Advanced Technology International
ATTN: (b) (6), Sr. Contracts Manager
315 Sigma Drive
Summerville, SC 29486

Dear (b) (6),

The Army Contracting Command – New Jersey (ACC-NJ), in supporting the Joint Project Manager – Medical Countermeasure Systems (JPM-MCS), issued MCDC RPP 20-11 on 09 June 2020. Members of the MCDC submitted proposals in accordance with this RPP. The Government received and evaluated all proposal(s) submitted and a Basis of Selection has been executed, selecting Pfizer, Inc. as the awardee. The Government requests that a Firm-Fixed-Price Project Agreement be issued to Pfizer, Inc. to award this proposal under Other Transaction Agreement W15QKN-16-9-1002, to be performed in accordance with the attached Government Statement of Work (SOW).

Based upon the acceptable update of Pfizer, Inc.'s proposal for "COVID-19 Pandemic – Large Scale Vaccine Manufacturing Demonstration" and 1) The Project Agreement Recipient's concurrence with the requirements included in the Government SOW; 2) An acceptable milestone schedule that meets SOW requirements, and; 3) The price proposed that has been analyzed by the Government, you are hereby directed to issue a Project Agreement to Pfizer, Inc. for the subject project. The total project value has been determined fair and reasonable and Pfizer, Inc.'s proposal has been selected IAW the above referenced Basis of Selection.

Already invoked in the Motion to Dismiss Brook Jackson's case (Apr 2022)